{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:35:23Z","timestamp":1780976123393,"version":"3.54.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Stent thrombosis (ST) is an uncommon but serious complication of stent implantation. This study aimed to explore factors associated with early, late, and very late ST to help guide risk assessment and clinical decision-making on ST.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The analysis included patients who received stent placement for the index acute coronary syndrome (ACS). Cumulative incidence of ST was assessed at 30 days (early ST), 31\u2013360 days (late ST), 361\u2013720 days (very late ST), and up to 720 days. Cox proportional hazards models were used to assess associations between ST and various factors, including patient characteristics [i.e., age, sex, ACS presentation, history of hypertension, smoking, diabetes, prior myocardial infarction (MI), heart failure, prior ischemic stroke, and cancer], laboratory tests [i.e., positive cardiac biomarker, hemoglobin, platelet count, white blood cell (WBC) count], and treatment [i.e., drug-eluting stent (DES) vs. bare-metal stent (BMS) and anticoagulant with rivaroxaban vs. placebo].<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 8,741 stented patients, 155 ST events (2.25%) occurred by Day 720. The cumulative incidences of early, late, and very late ST were 0.80%, 0.81%, and 0.77%, respectively. After multivariable adjustment, age\u2009\u2265\u200975 [hazard ratio (HR)\u2009=\u20092.13 (95% confidence interval, CI: 1.26\u20133.60)], a history of prior MI [HR\u2009=\u20091.81 (95% CI: 1.22\u20132.68)], low hemoglobin level [HR\u2009=\u20092.34 (95% CI: 1.59\u20133.44)], and high WBC count [HR\u2009=\u20091.58 (95% CI: 1.02\u20132.46)] were associated with a greater risk of overall ST, whereas DES [HR\u2009=\u20090.56 (95% CI: 0.38\u20130.83)] and rivaroxaban therapy [HR\u2009=\u20090.63 (95% CI: 0.44\u20130.88)] were associated with a lower risk of overall ST up to 720 days. Low hemoglobin level and high WBC count were associated with early ST (low hemoglobin: HR\u2009=\u20092.35 [95% CI: 1.34\u20134.12]; high WBC count: HR\u2009=\u20092.11 [95% CI: 1.17\u20133.81]). Low hemoglobin level and prior MI were associated with a greater risk of late ST (low hemoglobin: HR\u2009=\u20092.32 [95% CI: 1.26\u20134.27]; prior MI: HR\u2009=\u20092.98 [95% CI: 1.67\u20135.31]), whereas DES was associated with a lower risk of late ST [HR\u2009=\u20090.33 (95% CI: 0.16\u20130.67)]. Age \u226575\u2005years was associated with very late ST.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study identified positive and negative associations with early, late, and very late ST. These variables may be useful in constructing risk assessment models for ST.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:ext-link>http:\/\/www.clinicaltrials.gov<\/jats:ext-link>, identifier NCT00809965.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1269011","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:45:50Z","timestamp":1704689150000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial"],"prefix":"10.3389","volume":"10","author":[{"given":"Gerald","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"AlKhalfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar Memar","family":"Montazerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Korjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wally","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Barnathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Plotnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1093\/eurheartj\/ehv511","article-title":"Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gr\u00fcntzig Lecture ESC 2014","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/eurheartj\/ehi618","article-title":"Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12471-018-1113-5","article-title":"Optimal duration of dual antiplatelet therapy for coronary artery disease","volume":"26","author":"Kikkert","year":"2018","journal-title":"Netherlands Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41569-018-0118-5","article-title":"Predictors of stent thrombosis and their implications for clinical practice","volume":"16","author":"Gori","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e007822","DOI":"10.1161\/CIRCINTERVENTIONS.119.007822","article-title":"Risk factors and long-term clinical outcomes of second-generation drug-eluting stent thrombosis","volume":"12","author":"Kuramitsu","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"B8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1161\/CIRCINTERVENTIONS.111.965749","article-title":"The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents","volume":"5","author":"Pilgrim","year":"2012","journal-title":"Circ Cardiovasc Interventions"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jcin.2012.07.012","article-title":"Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes","volume":"5","author":"Dangas","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jacc.2018.02.023","article-title":"Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis","volume":"71","author":"Torrado","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","article-title":"Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome","volume":"161","author":"Gibson","year":"2011","journal-title":"Am Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjcard.2019.12.007","article-title":"Relation of white blood cell count to bleeding and ischemic events in patients with acute coronary syndrome (from the ATLAS ACS 2-TIMI 51 trial)","volume":"125","author":"Alkhalfan","year":"2020","journal-title":"Am J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0002-9149(03)00527-7","article-title":"Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes","volume":"92","author":"Bhatt","year":"2003","journal-title":"Am J Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0735-1097(02)02484-1","article-title":"Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 substudy","volume":"40","author":"Sabatine","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1161\/CIRCULATIONAHA.109.873695","article-title":"Mac-1 (CD11b\/CD18) is a critical molecular link between inflammation and thrombosis following glomerular injury1","volume":"120","author":"Hirahashi","year":"2009","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1001\/jama.1987.03390170074031","article-title":"Leukocytes and the risk of ischemic diseases","volume":"257","author":"Ernst","year":"1987","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1161\/01.CIR.102.19.2329","article-title":"Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy","volume":"102","author":"Barron","year":"2000","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1161\/01.CIR.89.1.36","article-title":"Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology","volume":"89","author":"van der Wal","year":"1994","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/heart.87.3.201","article-title":"Inflammation in acute coronary syndromes","volume":"87","author":"Mulvihill","year":"2002","journal-title":"Heart"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e5986","DOI":"10.1097\/MD.0000000000005986","article-title":"Association between RDW and stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"96","author":"Tun\u00e7ez","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/joic.12406","article-title":"Baseline anemia in patients undergoing percutaneous coronary intervention after an acute coronary syndrome\u2014a paradox of high bleeding risk, high ischemic risk, and complex coronary disease","volume":"30","author":"Yazji","year":"2017","journal-title":"J Interv Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00415-006-0411-9","article-title":"Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study","volume":"254","author":"Stolz","year":"2007","journal-title":"J Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"972.e1","DOI":"10.1016\/j.amjmed.2018.03.031","article-title":"Association of anemia with venous thromboembolism in acutely ill hospitalized patients: an APEX trial substudy","volume":"131","author":"Chi","year":"2018","journal-title":"Am J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J Anaesth"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e014294","DOI":"10.1136\/bmjopen-2016-014294","article-title":"Blood coagulation system in patients with chronic kidney disease: a prospective observational study","volume":"7","author":"Huang","year":"2017","journal-title":"BMJ Open"},{"key":"B28","first-page":"171","article-title":"Autoimmune diseases and venous thromboembolism: a review of the literature","volume":"2","author":"Z\u00f6ller","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","article-title":"Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia","volume":"67","author":"Livesey","year":"2012","journal-title":"Thorax"},{"key":"B30","doi-asserted-by":"publisher","first-page":"P445","DOI":"10.1186\/cc9865","article-title":"Effect of anemia on coagulation and platelet function: a whole blood in vitro study","volume":"15","author":"Scharbert","year":"2011","journal-title":"Critical Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJM199711273372203","article-title":"Circulating activated endothelial cells in sickle cell anemia","volume":"337","author":"Solovey","year":"1997","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.hoc.2013.11.005","article-title":"Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain","volume":"28","author":"Hebbel","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"B33","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1053\/ajkd.2003.50123","article-title":"Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients","volume":"41","author":"Yildiz","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary artery disease","volume":"375","author":"B\u00f8naa","year":"2016","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(19)30474-X","article-title":"Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials","volume":"393","author":"Piccolo","year":"2019","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jcin.2012.06.013","article-title":"Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction","volume":"5","author":"Brodie","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"B37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jcin.2013.09.008","article-title":"Two-year outcomes after first-or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia studY)","volume":"7","author":"Valgimigli","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1253\/circj.CJ-10-1160","article-title":"Characteristics and predictors of drug-eluting stent thrombosis","volume":"75","author":"Park","year":"2011","journal-title":"Circ J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jcin.2014.04.017","article-title":"Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (international drug-eluting stent event registry of thrombosis)","volume":"7","author":"Waksman","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry","volume":"53","author":"Van Werkum","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1161\/CIRCULATIONAHA.106.683995","article-title":"Late coronary stent thrombosis","volume":"116","author":"Windecker","year":"2007","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.1038\/s41598-023-37084-2","article-title":"Comparative effectiveness of cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry","volume":"13","author":"Pepe","year":"2023","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jacc.2010.07.016","article-title":"Stent thrombosis","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1161\/CIR.0000000000001039","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1269011\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:45:54Z","timestamp":1704689154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1269011\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":45,"alternative-id":["10.3389\/fcvm.2023.1269011"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1269011","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1269011"}}